Novo Nordisk (NVO) Total Debt (2014 - 2026)
Novo Nordisk (NVO) total debt from Dec 31, 2014 to Mar 31, 2026. The current Novo Nordisk (NVO) total debt is $55B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Total Debt
Total Debt
Novo Nordisk (NVO) Total Debt CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +49.96% |
| 3 Years TTM | +88.08% |
| 5 Years TTM | +92.89% |
| 10 Years TTM | +23.42% |
| All Time TTM | +22.97% |
Annual Total Debt change of Novo Nordisk (NVO)
| Year | Total Debt | Change |
|---|---|---|
| 2025 | $55B | +22.56% |
| 2024 | $45B | +45.36% |
| 2023 | $31B | +35.60% |
| 2022 | $23B | +19.95% |
| 2021 | $19B | +759.45% |
| 2020 | $2.20B | +43.57% |
| 2019 | $1.53B | -83.05% |
| 2018 | $9.05B | +6.88% |
| 2017 | $8.47B | +14.43% |
| 2016 | $7.40B | +13.41% |
| 2015 | $6.52B | +9.12% |
| 2014 | $5.98B | N/A |
Comparison Novo Nordisk (NVO) total debt with competitors
Novo Nordisk (NVO) total debt is $55.08B.
| Ticker | Name | Total Debt | Upside |
|---|---|---|---|
| MIRA | Mira Pharmaceuticals Inc | $114761.00 | -100.00% |
| NSRX | Nasus Pharma Ltd | $2.24M | -100.00% |
| MDCX | MDCorp | $6.00M | -99.99% |
| MDCXW | Medicus Pharma Ltd warrant | $6.00M | -99.99% |
| AMRN | Amarin Corp | $196.35M | -99.64% |
| SCLX | Scilex Holding Company | $547.71M | -99.01% |
| BIIB | Biogen Inc | $10.83B | -80.34% |
| OGN | Organon & Company | $12.09B | -78.05% |
| GRFS | Grifols SA | $12.24B | -77.77% |
| SNY | Sanofi | $54.88B | -0.37% |
| GSK | GSK Plc | $59.93B | +8.80% |
| BMY | Bristol-Myers Squibb Company | $66.37B | +20.50% |
| AZN | Astrazeneca plc | $66.63B | +20.96% |
| PFE | Pfizer Inc | $117.21B | +112.79% |
| JNJ | Johnson & Johnson | $119.71B | +117.32% |